127 related articles for article (PubMed ID: 38533552)
1. TAAR1 agonist ulotaront delays gastric emptying of solids in patients with schizophrenia and concurrent metabolic syndrome with prediabetes.
Milanović S; Dedic N; Lew R; Burton D; Koblan KS; Camilleri M; Hopkins SC
Diabetes Obes Metab; 2024 Jun; 26(6):2466-2475. PubMed ID: 38533552
[TBL] [Abstract][Full Text] [Related]
2. TAAR1 agonists improve glycemic control, reduce body weight and modulate neurocircuits governing energy balance and feeding.
Dedic N; Wang L; Hajos-Korcsok E; Hecksher-Sørensen J; Roostalu U; Vickers SP; Wu S; Anacker C; Synan C; Jones PG; Milanovic S; Hopkins SC; Bristow LJ; Koblan KS
Mol Metab; 2024 Feb; 80():101883. PubMed ID: 38237896
[TBL] [Abstract][Full Text] [Related]
3. Ulotaront: review of preliminary evidence for the efficacy and safety of a TAAR1 agonist in schizophrenia.
Achtyes ED; Hopkins SC; Dedic N; Dworak H; Zeni C; Koblan K
Eur Arch Psychiatry Clin Neurosci; 2023 Oct; 273(7):1543-1556. PubMed ID: 37165101
[TBL] [Abstract][Full Text] [Related]
4. Ulotaront: a TAAR1/5-HT1A agonist in clinical development for the treatment of schizophrenia.
Højlund M; Correll CU
Expert Opin Investig Drugs; 2022 Dec; 31(12):1279-1290. PubMed ID: 36533396
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Potential of TAAR1 Agonists in Schizophrenia: Evidence from Preclinical Models and Clinical Studies.
Dedic N; Dworak H; Zeni C; Rutigliano G; Howes OD
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34947997
[TBL] [Abstract][Full Text] [Related]
6. TAAR1 agonist ulotaront modulates striatal and hippocampal glutamate function in a state-dependent manner.
Yang SM; Ghoshal A; Hubbard JM; Gackière F; Teyssié R; Neale SA; Hopkins SC; Koblan KS; Bristow LJ; Dedic N
Neuropsychopharmacology; 2024 Jun; 49(7):1091-1103. PubMed ID: 38110609
[TBL] [Abstract][Full Text] [Related]
7. Ulotaront, a novel TAAR1 agonist with 5-HT1A agonist activity, lacks abuse liability and attenuates cocaine cue-induced relapse in rats.
Synan C; Bowen C; Heal DJ; Froger-Colléaux C; Beardsley PM; Dedic N; Hopkins SC; Campbell U; Koblan KS
Drug Alcohol Depend; 2022 Feb; 231():109261. PubMed ID: 35033729
[TBL] [Abstract][Full Text] [Related]
8. A New Treatment Paradigm: Targeting Trace Amine-Associated Receptor 1 (TAAR1) in Schizophrenia.
Kane JM
J Clin Psychopharmacol; 2022 Sep-Oct 01; 42(5 Suppl 1):S1-S13. PubMed ID: 36099402
[TBL] [Abstract][Full Text] [Related]
9. In Vitro Comparison of Ulotaront (SEP-363856) and Ralmitaront (RO6889450): Two TAAR1 Agonist Candidate Antipsychotics.
Ågren R; Betari N; Saarinen M; Zeberg H; Svenningsson P; Sahlholm K
Int J Neuropsychopharmacol; 2023 Sep; 26(9):599-606. PubMed ID: 37549917
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of OCT2-mediated drug-drug interactions between ulotaront and metformin in subjects with schizophrenia.
Xiao G; Tsukada H; Chen YL; Shi L; Hopkins SC; Galluppi GR
Pharmacol Res Perspect; 2024 Apr; 12(2):e1191. PubMed ID: 38527949
[TBL] [Abstract][Full Text] [Related]
11. A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight.
Revel FG; Moreau JL; Pouzet B; Mory R; Bradaia A; Buchy D; Metzler V; Chaboz S; Groebke Zbinden K; Galley G; Norcross RD; Tuerck D; Bruns A; Morairty SR; Kilduff TS; Wallace TL; Risterucci C; Wettstein JG; Hoener MC
Mol Psychiatry; 2013 May; 18(5):543-56. PubMed ID: 22641180
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, safety, and tolerability of ulotaront (SEP-363856, a trace amine-associated receptor 1 agonist) for the treatment of schizophrenia and other mental disorders: a systematic review of preclinical and clinical trials.
Le GH; Gillissie ES; Rhee TG; Cao B; Alnefeesi Y; Guo Z; Di Vincenzo JD; Jawad MY; March AM; Ramachandra R; Lui LMW; McIntyre RS
Expert Opin Investig Drugs; 2023 May; 32(5):401-415. PubMed ID: 37096491
[TBL] [Abstract][Full Text] [Related]
13. A randomized, single-dose, crossover study of the effects of ulotaront on electrocardiogram intervals in subjects with schizophrenia.
Tsukada H; Milanovic SM; Darpo B; Xue H; Xiong K; Tripp E; Lennek L; Worden M; Hopkins SC; Galluppi GR
Clin Transl Sci; 2023 Jun; 16(6):1063-1074. PubMed ID: 36949248
[TBL] [Abstract][Full Text] [Related]
14. Ulotaront: A TAAR1 Agonist for the Treatment of Schizophrenia.
Heffernan MLR; Herman LW; Brown S; Jones PG; Shao L; Hewitt MC; Campbell JE; Dedic N; Hopkins SC; Koblan KS; Xie L
ACS Med Chem Lett; 2022 Jan; 13(1):92-98. PubMed ID: 35047111
[TBL] [Abstract][Full Text] [Related]
15. Treatment with the novel TAAR1 agonist ulotaront is associated with reductions in quantitative polysomnographic REM sleep without atonia in healthy human subjects: Results of a post-hoc analysis.
Feemster JC; Westerland SM; Gossard TR; Steele TA; Timm PC; Jagielski JT; Strainis E; McCarter SJ; Hopkins SC; Koblan KS; St Louis EK
Sleep Med; 2023 Jan; 101():578-586. PubMed ID: 36584503
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetic analysis of ulotaront in subjects with schizophrenia.
Galluppi GR; Polhamus DG; Fisher JM; Hopkins SC; Koblan KS
CPT Pharmacometrics Syst Pharmacol; 2021 Oct; 10(10):1245-1254. PubMed ID: 34292664
[TBL] [Abstract][Full Text] [Related]
17. A multicenter, double-blind, placebo-controlled, randomized, Phase 1b crossover trial comparing two doses of ulotaront with placebo in the treatment of narcolepsy-cataplexy.
Szabo ST; Hopkins SC; Lew R; Loebel A; Roth T; Koblan KS
Sleep Med; 2023 Jul; 107():202-211. PubMed ID: 37209427
[TBL] [Abstract][Full Text] [Related]
18. Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study.
Correll CU; Koblan KS; Hopkins SC; Li Y; Heather Dworak ; Goldman R; Loebel A
NPJ Schizophr; 2021 Dec; 7(1):63. PubMed ID: 34887427
[TBL] [Abstract][Full Text] [Related]
19. In Vitro ADME and Preclinical Pharmacokinetics of Ulotaront, a TAAR1/5-HT
Xiao G; Chen YL; Dedic N; Xie L; Koblan KS; Galluppi GR
Pharm Res; 2022 May; 39(5):837-850. PubMed ID: 35484370
[TBL] [Abstract][Full Text] [Related]
20. Unlocking the Therapeutic Potential of Ulotaront as a Trace Amine-Associated Receptor 1 Agonist for Neuropsychiatric Disorders.
Kuvarzin SR; Sukhanov I; Onokhin K; Zakharov K; Gainetdinov RR
Biomedicines; 2023 Jul; 11(7):. PubMed ID: 37509616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
